Lenacapavir 300 MG Oral Tablet [Sunlenca] — RxCUI 2625896
What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.
🗂️ Key Facts
📖 Skip the Codes — Read It in Plain English.
Our pharmacist-built guide to Lenacapavir Oral: what it is, how it’s used, side effects, and interactions.
- Lenacapavir works by targeting the HIV virus's outer protein shell — called the capsid — which disrupts its ability to replicate. The oral tablets serve a specific purpose at the s...
- What exactly does lenacapavir do, and why do I need the tablets if there's also an injection?
- Yes, absolutely — this is one of the most important things to know. You must be tested for HIV-1 before every single injection using a sensitive FDA-approved test, not just when yo...
- I'm taking Yeztugo to prevent HIV — do I still need to get tested regularly?
🕸️ Concept Web — How Lenacapavir 300 MG Oral Tablet [Sunlenca] Connects
RxCUI 2625896 Semantic branded drug · SBD
Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.
-
Ingredients 1
The active substance itself — no strength, form, or brand attached yet.
-
Lenacapavir
2625651IN
-
Lenacapavir
-
Brand names 1
The same medicine's trade names. A brand name alone says nothing about strength or form.
-
Sunlenca
2625891BN
-
Sunlenca
-
Dose forms 9
The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.
-
Lenacapavir Oral Tablet
2625889SCDF -
Lenacapavir Oral Product
2625887SCDG -
Lenacapavir Pill
2625888SCDG -
Lenacapavir Oral Tablet [Sunlenca]
2625895SBDF -
Sunlenca Oral Product
2625893SBDG -
Sunlenca Pill
2625894SBDG -
Oral Tablet
317541DF -
Oral Product
1151131DFG - +1 more in this family
-
Lenacapavir Oral Tablet
-
Clinical & branded drugs 3
Ingredient + strength + dose form. These are the concepts real FDA products actually carry.
-
Lenacapavir 300 MG Oral Tablet
2625890SCD -
Lenacapavir 300 MG
2625886SCDC -
Lenacapavir 300 MG [Sunlenca]
2625892SBDC
-
Lenacapavir 300 MG Oral Tablet
-
Packs 4
Fixed collections of drugs packaged and sold together, like dose packs.
🔀 Generic ⇄ Brand Crosswalk
Generic (Clinical) Concepts
-
Lenacapavir 300 MG Oral Tablet
SCD · 2625890 -
{4 (lenacapavir 300 MG Oral Tablet) } Pack
GPCK · 2625897 -
{5 (lenacapavir 300 MG Oral Tablet) } Pack
GPCK · 2625899 -
Lenacapavir 300 MG
SCDC · 2625886 -
Lenacapavir Oral Tablet
SCDF · 2625889 -
Lenacapavir Oral Product
SCDG · 2625887 -
Lenacapavir Pill
SCDG · 2625888
Brand-Name Concepts
-
{4 (lenacapavir 300 MG Oral Tablet [Sunlenca]) } Pack [Sunlenca 4-Tablet Pack]
BPCK · 2625898 -
{5 (lenacapavir 300 MG Oral Tablet [Sunlenca]) } Pack [Sunlenca 5-Tablet Pack]
BPCK · 2625900 -
Lenacapavir 300 MG [Sunlenca]
SBDC · 2625892 -
Lenacapavir Oral Tablet [Sunlenca]
SBDF · 2625895 -
Sunlenca Oral Product
SBDG · 2625893 -
Sunlenca Pill
SBDG · 2625894 -
Sunlenca
BN · 2625891
📦 FDA Products & Package NDCs
3 products · 5 package NDCs
| Package NDC | Package | Brand / generic name | Labeler | Marketing start |
|---|---|---|---|---|
| 61958-3001-01 | 1 POUCH in 1 CARTON (61958-3001-1) / 1 BLISTER PACK in 1 PO... | Sunlenca | Gilead Sciences, Inc. | 2022-12-22 |
| 61958-3001-02 | 1 POUCH in 1 CARTON (61958-3001-2) / 1 BLISTER PACK in 1 PO... | Sunlenca | Gilead Sciences, Inc. | 2022-12-22 |
| 61958-3001-03 | 4 TABLET, FILM COATED in 1 BOTTLE, PLASTIC (61958-3001-3) | Sunlenca | Gilead Sciences, Inc. | 2024-11-13 |
| 61958-3002-01 | 1 KIT in 1 CARTON (61958-3002-1) * 1.5 mL in 1 VIAL (61958... | Sunlenca | Gilead Sciences, Inc. | 2022-12-22 |
| 61958-3005-01 | 1 KIT in 1 CARTON (61958-3005-1) * 1.5 mL in 1 VIAL (61958... | Sunlenca | Gilead Sciences, Inc. | 2025-03-18 |
🧾 Billing Codes (HCPCS)
| Code | Descriptor | Mapped packages | Sources |
|---|---|---|---|
| J1961 | Inj lenacapavir (hiv tx) 1mg | 2 | CMS |
🗃️ Sources & Limits
- A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
- Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
- Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
- Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.